What Is Orforglipron (Foundayo)? Mechanism, Maker & Pronunciation

Orforglipron is the first oral GLP-1 pill approved for weight loss. Its US brand name is Foundayo, it is made by Eli Lilly and Company, and the FDA approved it on April 1, 2026 for chronic weight management in adults with obesity or overweight with a weight-related medical condition^[1][2]. This article is the foundational explainer: what orforglipron is as a drug, who makes it, how the small-molecule GLP-1 mechanism works, what it is approved for, how effective it is in trials, what it costs, and how to pronounce the name.

What is orforglipron?

Orforglipron is the generic (international nonproprietary) name for a prescription weight-management drug developed by Eli Lilly and Company. In the US it is sold under the brand name Foundayo^[1]. The drug was originally discovered by Chugai Pharmaceutical and licensed to Eli Lilly in 2018, and Lilly developed it through phase 1, 2, and 3 trials under the internal designation LY3502970^[2].

Pharmacologically, orforglipron is a non-peptide, small-molecule GLP-1 receptor agonist^[1]. Translated into plain language: it binds and activates the same receptor (the glucagon-like peptide-1 receptor) that semaglutide, tirzepatide, liraglutide, and every other GLP-1 weight-loss drug binds and activates — but unlike those drugs, it is not a peptide. That single chemistry distinction is the reason orforglipron can be taken as a swallowable tablet rather than as an injection. We unpack that mechanism in detail below.

Foundayo is supplied as a once-daily oral tablet in six labeled strengths — 0.8 mg, 2.5 mg, 5.5 mg, 9 mg, 14.5 mg, and 17.2 mg (the labeled maximum) — taken at any time of day with or without food, and with no water restrictions^[1]. The half-life per the FDA prescribing information is 29-49 hours, much shorter than injectable semaglutide (~7 days) or injectable tirzepatide (~5 days), which is why it is dosed once daily instead of once weekly^[1].

One important labeled drug-drug interaction: when co-administered with a strong CYP3A4 inhibitor (e.g., clarithromycin, itraconazole, ketoconazole, or ritonavir-boosted antivirals), the maximum labeled Foundayo dose is reduced to 9 mg once daily^[1]. Orforglipron is metabolized primarily by CYP3A4, so strong inhibitors raise drug exposure meaningfully and the label caps the dose accordingly.

Who makes orforglipron?

Orforglipron is manufactured and marketed by Eli Lilly and Company, the Indianapolis-based pharmaceutical company that also makes Mounjaro and Zepbound (the brand names for tirzepatide, the injectable dual GIP/GLP-1 agonist FDA-approved for type 2 diabetes and chronic weight management, respectively)^[2]. Lilly is one of the two companies that effectively created the modern incretin weight-loss market — the other being Novo Nordisk, which makes semaglutide (Ozempic, Wegovy, Rybelsus).

Lilly's strategic rationale for developing an oral small-molecule GLP-1 is straightforward. Injectable GLP-1 drugs are extraordinarily effective but the manufacturing is constrained: peptide synthesis is slow, expensive, and requires sterile injectable formulation. A small-molecule oral drug is dramatically cheaper to manufacture, can be scaled the way an ordinary tablet is scaled, and removes the needle-phobia barrier that keeps a meaningful fraction of eligible patients off the injectable GLP-1 class entirely. Lilly has publicly stated that orforglipron was engineered specifically to be the GLP-1 that closes those gaps^[2].

How does orforglipron work?

Orforglipron is a GLP-1 receptor agonist, which means it activates the same receptor that the body's own glucagon-like peptide-1 hormone activates after a meal. The downstream effects of GLP-1 receptor activation are well characterized^[1]:

• Appetite suppression. GLP-1 receptors in the hypothalamus and brainstem reduce hunger signaling and reward-driven eating, so patients feel less hungry between meals and are satisfied with smaller portions.
• Slowed gastric emptying. GLP-1 activation slows the rate at which the stomach passes food into the small intestine, which prolongs the feeling of fullness after a meal.
• Increased satiety. The combined central and peripheral effects produce earlier and longer-lasting satiety, which is what drives the sustained calorie deficit that produces the trial-reported weight loss.
• Glucose-dependent insulin secretion. GLP-1 stimulates insulin release from pancreatic beta cells when blood glucose is elevated, which is why GLP-1 drugs are also used for type 2 diabetes (orforglipron is being studied separately in diabetes under the ATTAIN-2 program).

The chemistry detail that matters: every other FDA-approved GLP-1 receptor agonist (semaglutide, tirzepatide, liraglutide, dulaglutide, exenatide) is a peptide — a short chain of amino acids. Peptides are digested in the stomach, which is why all of them need to be injected to survive into the bloodstream. The one partial exception is Rybelsus (oral semaglutide for type 2 diabetes), which is peptide semaglutide formulated with an absorption enhancer called SNAC and which has to be taken on an empty stomach with no more than 4 ounces of water followed by a 30-minute wait before eating, drinking, or taking other oral medications^[2].

Orforglipron is not a peptide at all. It is a small organic molecule designed from the ground up to bind the GLP-1 receptor in the same orientation as the natural peptide ligand. Because it is a small molecule, it survives stomach acid and the digestive enzymes that destroy peptides, it does not require an absorption enhancer, and it does not require any food or water restrictions^[1]. That is the reason it works as an ordinary swallowable tablet — and the reason it is the first true oral GLP-1 ever approved for weight loss.

What is orforglipron used for?

The FDA-approved indication for Foundayo is chronic weight management in adults who meet either of the following criteria^[1]:

• BMI of 30 kg/m² or higher (the clinical definition of obesity), or
• BMI of 27 kg/m² or higher (overweight) plus at least one weight-related medical condition such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or cardiovascular disease.

Foundayo is intended to be used as an adjunct to a reduced-calorie diet and increased physical activity, the same wraparound prescribing language that appears on every FDA-approved chronic weight management drug^[1].

Orforglipron is also being investigated for type 2 diabetes (ATTAIN-2), obstructive sleep apnea, knee osteoarthritis, hypertension, and several other indications, but as of April 2026 the only FDA-approved use is the chronic weight management indication described above^[2]. For the full ATTAIN-1 trial breakdown and efficacy estimands, see our Foundayo FDA approval deep-dive.

How is it different from other GLP-1s?

The simplest framing is the form-vs-effect-size trade-off. Foundayo is the only oral option in the GLP-1 weight-loss class. The injectables produce more weight loss on average, but require a needle. Here is how the four major GLP-1 weight-loss drugs compare on the dimensions patients actually care about:

For a head-to-head walkthrough that includes pricing, side-effect profile, and the case for choosing each drug, see our Foundayo vs Wegovy vs Zepbound comparison.

How effective is orforglipron?

Foundayo's approval was anchored on the ATTAIN-1 phase 3 trial, a 72-week randomized, double-blind, placebo-controlled trial in 3,127 adults with obesity or overweight without type 2 diabetes (the T2D population is being studied separately under the ATTAIN-2 / ACHIEVE program)^[3]. The FDA-labeled mean weight loss at the labeled maximum 17.2 mg dose was approximately 11.1% (about 24.9 pounds) over 72 weeks in the non-diabetic population per the Foundayo prescribing information^[1].

Honest framing: Foundayo's effect size sits below injectable semaglutide and well below tirzepatide. STEP-1 reported about 14.9% mean weight loss for Wegovy 2.4 mg weekly, and SURMOUNT-1 reported about 20.9% for Zepbound 15 mg weekly. The trade-off Foundayo offers patients is roughly 3-10 percentage points less weight loss in exchange for a daily pill that requires no needles, no cold-chain shipping, and no sharps disposal. For patients who would not otherwise start a GLP-1 because of injection burden, that trade-off is the entire point of the drug.

What does orforglipron cost?

Foundayo's US list price is approximately $999 per month at the labeled doses. The most relevant out-of-pocket numbers for actual patients depend on the access path^[2]:

• Commercial insurance + Lilly Savings Card: as low as $25 per month for commercially insured patients (not Medicare or Medicaid). This is the cheapest legal path to a brand-name FDA-approved GLP-1 in 2026 by a wide margin.
• Cash pay through LillyDirect: $149 per month for the lowest dose, scaling up at the higher labeled doses.
• Medicare Part D: does NOT cover Foundayo for the weight management indication. Section 1860D-2(e)(2)(A) of the Social Security Act explicitly excludes agents used for weight loss from Medicare Part D coverage, which means no FDA-approved GLP-1 obesity drug (Wegovy, Zepbound, Saxenda, or Foundayo) is currently covered by Part D for weight management. Medicare beneficiaries who want Foundayo for weight management must pay cash.

For the live provider directory and the channel-by-channel pricing, see our Where to buy Foundayo provider list. To compare cost-per-pound of weight loss across every FDA-approved GLP-1, use our GLP-1 cost-per-pound calculator.

How do you pronounce orforglipron?

The standard English pronunciation is or-for-GLI-pron — four syllables, with the stress on the third syllable (GLI). Broken out:

• or — as in “or”
• for — as in “for”
• GLI — as in “glee” (stressed)
• pron — rhymes with “Ron”

Eli Lilly has not published an official pronunciation guide for orforglipron as of this article's publication date, so this is the standard English reading of the spelling rather than a manufacturer-confirmed pronunciation. The brand name Foundayo is pronounced “foun-DAY-oh” — three syllables, stress on the second.

Frequently asked questions

Is orforglipron the same as Foundayo?

Yes. Orforglipron is the generic (chemical) name and Foundayo is the US brand name. They refer to the same Eli Lilly small-molecule GLP-1 receptor agonist tablet. Both names appear on the FDA-approved label^[1].

When was orforglipron FDA-approved?

The FDA approved Foundayo (orforglipron) on April 1, 2026 for chronic weight management in adults with obesity or overweight with at least one weight-related medical problem. Commercial dispensing through LillyDirect began April 6, 2026^[2].

Is orforglipron a pill or an injection?

Orforglipron is a once-daily oral tablet — it is the first GLP-1 receptor agonist ever approved for weight loss in pill form. Every other GLP-1 weight-loss drug (Wegovy, Zepbound, Saxenda) is a subcutaneous injection^[1]. For the full daily protocol, see our how to take Foundayo guide.

Does orforglipron work as well as Ozempic or Zepbound?

Not on average. At the labeled maximum 17.2 mg dose Foundayo produced about 11.1% mean weight loss over 72 weeks. Wegovy STEP-1 reported about 14.9%, and Zepbound SURMOUNT-1 reported about 20.9% at the 15 mg dose. Foundayo is less effective than the best injectables but is the only oral option^[1][3].

Who is orforglipron for?

Adults with obesity (BMI of 30 or higher) or adults with overweight (BMI of 27 or higher) plus at least one weight-related condition such as hypertension, dyslipidemia, obstructive sleep apnea, type 2 diabetes, or cardiovascular disease^[1].

How do you say orforglipron?

Or-for-GLI-pron — four syllables with the stress on the third syllable (GLI). Lilly has not published an official pronunciation guide, so this is the standard English reading of the spelling.

Related research and tools

• Foundayo (orforglipron) FDA approval deep-dive — full ATTAIN-1 trial review, dosing, and the approval narrative
• Foundayo vs Wegovy vs Zepbound head-to-head — trial efficacy, pricing, and the case for each drug
• Where to buy Foundayo in 2026 — verified provider directory and channel-by-channel pricing
• How to take Foundayo — daily protocol, food rules, missed-dose handling
• Best orforglipron providers — ranked list of telehealth platforms prescribing Foundayo
• GLP-1 cost-per-pound calculator — compare Foundayo, Wegovy, and Zepbound on dollars per pound lost

Important disclaimer. This article is educational and does not constitute medical advice. Foundayo (orforglipron) is a prescription drug with a boxed warning for thyroid C-cell tumors and several other class warnings — it should only be used under the supervision of a licensed prescribing clinician. Pricing and availability change frequently in the first weeks of any new drug launch; verify directly with the prescriber and pharmacy. Weight Loss Rankings has no financial relationship with Eli Lilly.